View Older Stories View More Recent Stories

Nov 5, 2024 09:29AM Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Oct 31, 2024 09:29AM Genprex to Participate in 2024 BIO Europe Conference
Oct 28, 2024 09:30AM Genprex (GNPX) Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
Oct 28, 2024 09:29AM Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
Oct 24, 2024 09:30AM Genprex (GNPX) Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
Oct 24, 2024 09:29AM Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
Oct 15, 2024 09:29AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Ex
Oct 15, 2024 09:29AM Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive
Oct 10, 2024 09:29AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Oct 7, 2024 09:29AM Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Sep 23, 2024 09:29AM Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Sep 19, 2024 09:29AM Genprex (GNPX) Forms Mesothelioma Clinical Advisory Board
Sep 19, 2024 09:29AM Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Sep 9, 2024 09:29AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Sep 4, 2024 09:29AM Genprex (GNPX) to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Sep 4, 2024 09:29AM Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Sep 3, 2024 08:15AM Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Aug 15, 2024 09:30AM Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Aug 14, 2024 09:25AM Genprex (GNPX) Reports Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Trials
Aug 14, 2024 09:25AM Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
Aug 13, 2024 08:31AM Genprex (GNPX) Granted Patent in Singapore for Reqorsa Gene Therapy
Aug 13, 2024 08:31AM Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
Aug 8, 2024 08:30AM Genprex to Present at the August Sidoti Microcap Conference
Jun 27, 2024 08:31AM Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
May 30, 2024 08:31AM Genprex to Present at the 2024 BIO International Convention
May 14, 2024 08:31AM Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
May 13, 2024 08:31AM Genprex (GNPX) Appoints Jose A. Moreno Toscano as Board Chair
May 13, 2024 08:31AM Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
May 8, 2024 06:08PM Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
May 1, 2024 08:31AM Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
Apr 9, 2024 08:37AM Genprex (GNPX) Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers
Apr 9, 2024 08:31AM Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AA
Apr 3, 2024 08:31AM Genprex (GNPX) Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Apr 3, 2024 08:31AM Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Apr 2, 2024 08:31AM Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Mar 22, 2024 04:10PM Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 19, 2024 01:25PM Genprex (GNPX) Announces 1.54M Share Offering at $4.215/sh
Mar 19, 2024 01:24PM Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 19, 2024 08:38AM Genprex (GNPX) Announces $6.5 Million Registered Direct Offering of Common Stock, Warrants
Mar 19, 2024 08:36AM Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 12, 2024 09:02AM Genprex (GNPX) Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Mar 12, 2024 09:01AM Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Mar 6, 2024 08:30AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 202
Feb 7, 2024 08:16AM Genprex (GNPX) Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Feb 7, 2024 08:15AM Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Feb 6, 2024 07:30AM Genprex to Present at Upcoming BIO CEO & Investor Conference
Feb 5, 2024 07:30AM Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Jan 31, 2024 08:42AM Genprex (GNPX) Announces 1:40 Reverse Stock Split
Jan 31, 2024 08:42AM Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
Jan 5, 2024 07:02AM Genprex (GNPX) Provides Business Update and Outlook for 2024
View More Recent Stories View Older Stories